Phase 1 Randomized Double-Blind Placebo-Controlled Study of GTX-B001 in Cold Induced Urticaria and Healthy Volunteers

The primary objective of this clinical trial is to evaluate the **tolerability**, **pharmacokinetics**, **pharmacodynamics**, and preliminary **efficacy** of GTX-B001 in both healthy volunteers and patients diagnosed with **Cold Induced Urticaria**. This study is designed to assess the safety profile and biological activity of the investigational product, which is crucial for understanding its potential therapeutic benefits and risks in the target population. The trial is structured as a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study, which is a standard approach for early-stage clinical trials aimed at gathering initial data on drug safety and biological effects.

The clinical trial involves participants diagnosed with **Cold Induced Urticaria**. The study population includes both male and female subjects, with an age range categorized as adults. The trial population was selected to include a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Participants' general health status, lifestyle considerations such as diet, physical activity, or habits, and key inclusion or exclusion criteria are not specified in the available data.

The clinical trial is a **Phase 1**, randomized, double-blind, placebo-controlled study designed to evaluate the tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of GTX-B001. The trial is divided into two parts: Part A involves healthy volunteers, while Part B focuses on patients with **Cold Induced Urticaria**. The estimated recruitment start date is September 26, 2025, with an anticipated end date of October 1, 2026. The trial will follow a single ascending dose methodology to assess the safety and initial efficacy of the investigational product.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a comprehensive assessment, including medical history, physical examination, and laboratory tests. Following successful screening, participants will be randomized to receive either the investigational product or a placebo. The trial design ensures that neither the participants nor the investigators know which treatment is being administered, maintaining the double-blind nature of the study.

Subsequent follow-up visits will be scheduled to monitor participants' health, collect pharmacokinetic and pharmacodynamic data, and assess any adverse events. These visits are crucial for evaluating the investigational product's safety profile and its effects on the participants. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the investigational product's impact.

The expected length of participant involvement will vary depending on the dosing schedule and the number of follow-up visits required. Participants may be withdrawn from the study early if they experience significant adverse events, fail to comply with study procedures, or withdraw consent. The trial's design and procedures are structured to ensure the collection of robust data while prioritizing participant safety and adherence to ethical standards.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

No specific details regarding the assessment of efficacy in the clinical trial are provided in the available data. Information such as the parameters or endpoints used to evaluate efficacy, the methods and schedule for measuring, collecting, and analyzing these parameters, and any tools or instruments involved in efficacy assessments are not included. The trial is identified as a Phase 1 study, with an estimated recruitment start date of September 26, 2025, and an estimated end date of October 1, 2026. Further details on efficacy assessment are not available in the provided source material.